Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib
| Autor: | Peter Mayer, Janusz Jankowski, L. Price, Mark Anderson, K. Beddows, David Ferry |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Cisplatin Cancer Research medicine.medical_specialty Chemotherapy biology medicine.diagnostic_test business.industry medicine.drug_class medicine.medical_treatment medicine.disease Chemotherapy regimen Tyrosine-kinase inhibitor Gefitinib Internal medicine Biopsy medicine biology.protein Adenocarcinoma Epidermal growth factor receptor business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:4021-4021 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.22.90140.4021 |
| Popis: | 4021 Background: At presentation, most cases of adenocarcinoma of the oesophagus (ACO) are inoperable and, although chemotherapy with cisplatin/5-fluorouracil can prolong survival, patients eventually die as a result of refractory disease. Expression of epidermal growth factor receptor (EGFR) is a negative prognostic factor. EGFR is almost universally expressed in ACO; however, it is inhibited by the tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839). Methods: A Phase II clinical trial was conducted in patients with ACO who had received 1 previous chemotherapy regimen for advanced disease, relapsed after surgery and neoadjuvant chemotherapy, declined chemotherapy or been too ill for chemotherapy. A total of 27 patients were to be recruited using a 2-stage design. Biopsies were taken before and 28 days after treatment with gefitinib 500 mg/day. Tumour response was assessed using RECIST. Results: There were 23 men and 4 women with a median (range) age of 60 (46–82) years. Twenty patients had previous ch... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|